Avid Bioservices Inc (CDMO)

[Protector]

volgoat, the information is out since a few hours. How do you expect that even if someone would have applied we would even know about it. It was however already on Duke's board and in the Yale Journal.

As for:

Proposals focusing solely on preclinical studies

This is not correct, I don't understand why you write this as FACT while the document say the reverse:

3.0 Scope and Aims

The overall aim of this RFP is to develop innovative studies to help determine the role of bavituximab in expanding efficacy and/or improving outcomes for patients treated with immunotherapy, or with modalities that increase tumor antigenicity. It is hoped proposals submitted in response to this RFP will be useful in guiding further development of bavituximab. Studies with correlative endpoints are encouraged.

The areas of research emphasis identified for this RFP include:
• Phase I/II studies in any solid tumor type

PS: And by the way, from memory, Pembrolizumab is humanized!